MINI FUTURE OPTIONSSCHEIN PUT - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 20:34:54 08/07/2024 BST | After market 20:59:30 | |||
| 19.24 EUR | -3.85% |
|
19.3 | +0.34% |
| Current month | -5.81% | ||
| 1 month | +1.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/07/24 | 19.24 | -3.85% |
| 05/07/24 | 20.01 | -0.94% |
| 04/07/24 | 20.2 | -1.56% |
| 03/07/24 | 20.52 | +1.89% |
| 02/07/24 | 20.14 | -1.18% |
Real-time Boerse Frankfurt Warrants
Last update July 08, 2024 at 08:34 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DQ36LX |
| ISIN | DE000DQ36LX8 |
| Date issued | 05/06/2024 |
| Strike | 690.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 20.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.08 € |
|---|---|
| Lowest since issue | 18.62 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
471
USD
Spread / Average Target
-0.75%
- Stock Market
- Certificates
- Certificat
